Global Anti-angiogenic Ophthalmic Agents Market- Industry Analysis Forecast 2020-2026

Global Anti-angiogenic Ophthalmic Agents Market is expected to grow at a CAGR of xx% and accounting for a revenue share of $xx MN in 2026 from $xx MN in 2019.

Global Anti-angiogenic Ophthalmic Agents Market: Overview

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.

Global Anti-angiogenic Ophthalmic Agents Market: Dynamics

Increasing prevalence of Ocular diseases is the key driving factor for the market growth. Diabetic retinopathy remains one of the greatest challenges for healthcare system worldwide despite the fact that the incidence of visual acuity impairment in diabetic population has decreased due to examination quality improvement and dynamic observation of patients. According to the World Health Organization, a significant increase worldwide in number of patients with Diabetes Mellitus, is expected to reach 629 million by the year 2045. Along with this, rising prevalence of age-related macular degeneration (AMD), which is the leading cause of severe vision loss among geriatric population in many western countries is also bolstering the market growth. Many treatment options are available to treat the ocular diseases. The Laser Coagulation of the Retina (LCR) is used to treat diabetic retinal lesions. However, despite the proven efficacy of LCR some patients continue to lose their vision despite treatment. This may be due to both the complications of laser treatment (development of serpiginous atrophy and subretinal fibrosis) and resistance to its effects. This factor may restrain the market growth. The report has profiled twenty key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.

Global Anti-angiogenic Ophthalmic Agents Market: Segment Analysis

By Indication Type, Macular Edema segment is expected to dominate the market. Macular edema is the build-up of fluid in the macula, an area in the center of the retina. The retina is the light-sensitive tissue at the back of the eye and the macula is the part of the retina responsible for sharp, straight-ahead vision. Fluid buildup causes the macula to swell and thicken, which distorts vision. The current standard of care for macular edema is intravitreal injection or anti-VEGF injection. A recent NEI-supported clinical trial that directly compared the effectiveness of the three drugs for DME found that the drugs performed similarly for patients with mild vision problems. However, Eylea performed better for those with more serious vision loss. The global prevalence of Diabetic Macular Edema (DME) among individuals with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus varies by geographic region, with rates as low as 11.4% in European countries to as high as 45.3% in North American countries. Global Anti-angiogenic Ophthalmic Agents Market To Know About The Research Methodology :- Request Free Sample Report

Global Anti-angiogenic Ophthalmic Agents Market: Regional Insights

Global Anti-angiogenic Ophthalmic Agents Market1 North America accounted for largest market share in the year 2019, followed by Europe. Increasing prevalence of eye related disorders like AMD, cataract, glaucoma, diabetic retinopathy, diabetic macular edema and dry eye disorders in the region and high availability of commercialized Anti-angiogenic Ophthalmic Agents are some of the driving factors for market in the region. Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among people aged 65 years and over in the United States and many western countries. For instance, in 2019, Bausch + Lomb launched Ocuvite Eye Performance vitamin supplements in the U.S. in order to meet the increasing needs of U.S. consumers. Besides this, Europe held the second largest share owing to increasing prevalence of myopic choroidal neovascularization in the region. Asia Pacific is expected to witness fastest growth. Increasing prevalence of diabetes and other eye related disorders in Asian countries with rising geriatric population pool who are more susceptible in acquiring these vision impairments will contribute to the market growth. Global Anti-angiogenic Ophthalmic Agents Market2 The report also helps in understanding Global Anti-angiogenic Ophthalmic Agents Market dynamics, structure by analyzing the market segments and project the Global Anti-angiogenic Ophthalmic Agents Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-angiogenic Ophthalmic Agents Market make the report investor’s guide.

Scope of the Global Anti-angiogenic Ophthalmic Agents Market Report: Inquire before buying

Global Anti-angiogenic Ophthalmic Agents Market3

By Region:

• North America • Europe • South America • MEA • APAC

Key Players operating in Global Anti-angiogenic Ophthalmic Agents Market:

• Gilead Sciences, Inc. • Eyetech Inc. • Becton, Dickinson and Company • Regeneron Pharmaceuticals, Inc. • Genentech, Inc. • Novartis AG • Allergan plc • Bayer AG • Santen Pharmaceutical Co., Ltd. • Shanghai Pharmaceuticals • Johnson & Johnson • Pfizer • Sun Pharma • Otsuka Pharmaceutical Co. Ltd • Daiichi Sankyo • ERC Labs • Medicom Health care • Implandata ophthalmic products GmbH • The Geuder Group, MORCHER GmbH • Novamedika

Press Release:

According to the news released in October 2019, Novartis received FDA approval for Beovu, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept. Beovu is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy.

Global Anti-angiogenic Ophthalmic Agents Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Anti-angiogenic Ophthalmic Agents Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast 6.1. Anti-angiogenic Ophthalmic Agents Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast, By Indication Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 7.4. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Indication Type 7.5. Anti-angiogenic Ophthalmic Agents Market Analysis, By Indication Type 7.6. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Indication Type 8. Global Anti-angiogenic Ophthalmic Agents Market Analysis and Forecast, By Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 8.4. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Distribution Channel 8.5. Anti-angiogenic Ophthalmic Agents Market Analysis, By Distribution Channel 8.6. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Distribution Channel 9. Global Anti-angiogenic Ophthalmic Agents Market Analysis, By Region 9.1. Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Region 9.2. Anti-angiogenic Ophthalmic Agents Market Size (US$ Mn) Forecast, By Region 9.3. Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis, By Region 10. North America Anti-angiogenic Ophthalmic Agents Market Analysis 10.1. Key Findings 10.2. North America Anti-angiogenic Ophthalmic Agents Market Overview 10.3. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 10.4. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 10.4.1. Myopic Choroidal Neovascularization 10.4.2. Macular Edema 10.4.3. Diabetic Retinopathy 10.4.4. Macular Degeneration 10.5. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 10.6. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 10.6.1. Retail Pharmacies 10.6.2. Online pharmacies 10.6.3. Hospital pharmacies 10.7. North America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country 10.8. North America Anti-angiogenic Ophthalmic Agents Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America Anti-angiogenic Ophthalmic Agents Market Analysis, By Country 10.10. U.S. Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 10.10.1. Myopic Choroidal Neovascularization 10.10.2. Macular Edema 10.10.3. Diabetic Retinopathy 10.10.4. Macular Degeneration 10.11. U.S. Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 10.11.1. Retail Pharmacies 10.11.2. Online pharmacies 10.11.3. Hospital pharmacies 10.12. Canada Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 10.12.1. Myopic Choroidal Neovascularization 10.12.2. Macular Edema 10.12.3. Diabetic Retinopathy 10.12.4. Macular Degeneration 10.13. Canada Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 10.13.1. Retail Pharmacies 10.13.2. Online pharmacies 10.13.3. Hospital pharmacies 10.14. Mexico Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 10.14.1. Myopic Choroidal Neovascularization 10.14.2. Macular Edema 10.14.3. Diabetic Retinopathy 10.14.4. Macular Degeneration 10.15. Mexico Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 10.15.1. Retail Pharmacies 10.15.2. Online pharmacies 10.15.3. Hospital pharmacies 10.16. North America Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis 10.16.1. By Indication Type 10.16.2. By Distribution Channel 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe Anti-angiogenic Ophthalmic Agents Market Analysis 11.1. Key Findings 11.2. Europe Anti-angiogenic Ophthalmic Agents Market Overview 11.3. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 11.4. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.4.1. Myopic Choroidal Neovascularization 11.4.2. Macular Edema 11.4.3. Diabetic Retinopathy 11.4.4. Macular Degeneration 11.5. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 11.6. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.6.1. Retail Pharmacies 11.6.2. Online pharmacies 11.6.3. Hospital pharmacies 11.7. Europe Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country 11.8. Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.9.1. Myopic Choroidal Neovascularization 11.9.2. Macular Edema 11.9.3. Diabetic Retinopathy 11.9.4. Macular Degeneration 11.10. Germany Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.10.1. Retail Pharmacies 11.10.2. Online pharmacies 11.10.3. Hospital pharmacies 11.11. U.K. Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.11.1. Myopic Choroidal Neovascularization 11.11.2. Macular Edema 11.11.3. Diabetic Retinopathy 11.11.4. Macular Degeneration 11.12. U.K. Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.12.1. Retail Pharmacies 11.12.2. Online pharmacies 11.12.3. Hospital pharmacies 11.13. France Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.13.1. Myopic Choroidal Neovascularization 11.13.2. Macular Edema 11.13.3. Diabetic Retinopathy 11.13.4. Macular Degeneration 11.14. France Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.14.1. Retail Pharmacies 11.14.2. Online pharmacies 11.14.3. Hospital pharmacies 11.15. Italy Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.15.1. Myopic Choroidal Neovascularization 11.15.2. Macular Edema 11.15.3. Diabetic Retinopathy 11.15.4. Macular Degeneration 11.16. Italy Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.16.1. Retail Pharmacies 11.16.2. Online pharmacies 11.16.3. Hospital pharmacies 11.17. Spain Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.17.1. Myopic Choroidal Neovascularization 11.17.2. Macular Edema 11.17.3. Diabetic Retinopathy 11.17.4. Macular Degeneration 11.18. Spain Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.18.1. Retail Pharmacies 11.18.2. Online pharmacies 11.18.3. Hospital pharmacies 11.19. Sweden Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.19.1. Myopic Choroidal Neovascularization 11.19.2. Macular Edema 11.19.3. Diabetic Retinopathy 11.19.4. Macular Degeneration 11.20. Sweden Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.20.1. Retail Pharmacies 11.20.2. Online pharmacies 11.20.3. Hospital pharmacies 11.21. CIS countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.21.1. Myopic Choroidal Neovascularization 11.21.2. Macular Edema 11.21.3. Diabetic Retinopathy 11.21.4. Macular Degeneration 11.22. CIS countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.22.1. Retail Pharmacies 11.22.2. Online pharmacies 11.22.3. Hospital pharmacies 11.23. Rest of Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 11.23.1. Myopic Choroidal Neovascularization 11.23.2. Macular Edema 11.23.3. Diabetic Retinopathy 11.23.4. Macular Degeneration 11.24. Rest of Europe Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 11.24.1. Retail Pharmacies 11.24.2. Online pharmacies 11.24.3. Hospital pharmacies 11.25. Europe Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis 11.25.1. By Distribution Channel 11.25.2. By Indication Type 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Analysis 12.1. Key Findings 12.2. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Overview 12.3. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 12.4. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.4.1. Myopic Choroidal Neovascularization 12.4.2. Macular Edema 12.4.3. Diabetic Retinopathy 12.4.4. Macular Degeneration 12.5. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 12.6. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.6.1. Retail Pharmacies 12.6.2. Online pharmacies 12.6.3. Hospital pharmacies 12.7. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country 12.8. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Analysis, By Country 12.10. China Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.10.1. Myopic Choroidal Neovascularization 12.10.2. Macular Edema 12.10.3. Diabetic Retinopathy 12.10.4. Macular Degeneration 12.11. China Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.11.1. Retail Pharmacies 12.11.2. Online pharmacies 12.11.3. Hospital pharmacies 12.12. India Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.12.1. Myopic Choroidal Neovascularization 12.12.2. Macular Edema 12.12.3. Diabetic Retinopathy 12.12.4. Macular Degeneration 12.13. India Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.13.1. Retail Pharmacies 12.13.2. Online pharmacies 12.13.3. Hospital pharmacies 12.14. Japan Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.14.1. Myopic Choroidal Neovascularization 12.14.2. Macular Edema 12.14.3. Diabetic Retinopathy 12.14.4. Macular Degeneration 12.15. Japan Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.15.1. Retail Pharmacies 12.15.2. Online pharmacies 12.15.3. Hospital pharmacies 12.16. South Korea Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.16.1. Myopic Choroidal Neovascularization 12.16.2. Macular Edema 12.16.3. Diabetic Retinopathy 12.16.4. Macular Degeneration 12.17. South Korea Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.17.1. Retail Pharmacies 12.17.2. Online pharmacies 12.17.3. Hospital pharmacies 12.18. Australia Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.18.1. Myopic Choroidal Neovascularization 12.18.2. Macular Edema 12.18.3. Diabetic Retinopathy 12.18.4. Macular Degeneration 12.19. Australia Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.19.1. Retail Pharmacies 12.19.2. Online pharmacies 12.19.3. Hospital pharmacies 12.20. ASEAN Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.20.1. Myopic Choroidal Neovascularization 12.20.2. Macular Edema 12.20.3. Diabetic Retinopathy 12.20.4. Macular Degeneration 12.21. ASEAN Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.21.1. Retail Pharmacies 12.21.2. Online pharmacies 12.21.3. Hospital pharmacies 12.22. Rest of Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 12.22.1. Myopic Choroidal Neovascularization 12.22.2. Macular Edema 12.22.3. Diabetic Retinopathy 12.22.4. Macular Degeneration 12.23. Rest of Asia Pacific Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 12.23.1. Retail Pharmacies 12.23.2. Online pharmacies 12.23.3. Hospital pharmacies 12.24. Asia Pacific Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis 12.24.1. By Indication Type 12.24.2. By Distribution Channel 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Overview 13.3. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 13.4. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.4.1. Myopic Choroidal Neovascularization 13.4.2. Macular Edema 13.4.3. Diabetic Retinopathy 13.4.4. Macular Degeneration 13.5. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 13.6. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.6.1. Retail Pharmacies 13.6.2. Online pharmacies 13.6.3. Hospital pharmacies 13.7. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country 13.8. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Analysis, By Country 13.10. GCC Countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.10.1. Myopic Choroidal Neovascularization 13.10.2. Macular Edema 13.10.3. Diabetic Retinopathy 13.10.4. Macular Degeneration 13.11. GCC Countries Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.11.1. Retail Pharmacies 13.11.2. Online pharmacies 13.11.3. Hospital pharmacies 13.12. South Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.12.1. Myopic Choroidal Neovascularization 13.12.2. Macular Edema 13.12.3. Diabetic Retinopathy 13.12.4. Macular Degeneration 13.13. South Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.13.1. Retail Pharmacies 13.13.2. Online pharmacies 13.13.3. Hospital pharmacies 13.14. Nigeria Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.14.1. Myopic Choroidal Neovascularization 13.14.2. Macular Edema 13.14.3. Diabetic Retinopathy 13.14.4. Macular Degeneration 13.15. Nigeria Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.15.1. Retail Pharmacies 13.15.2. Online pharmacies 13.15.3. Hospital pharmacies 13.16. Egypt Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.16.1. Myopic Choroidal Neovascularization 13.16.2. Macular Edema 13.16.3. Diabetic Retinopathy 13.16.4. Macular Degeneration 13.17. Egypt Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.17.1. Retail Pharmacies 13.17.2. Online pharmacies 13.17.3. Hospital pharmacies 13.18. Rest of Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 13.18.1. Myopic Choroidal Neovascularization 13.18.2. Macular Edema 13.18.3. Diabetic Retinopathy 13.18.4. Macular Degeneration 13.19. Rest of Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 13.19.1. Retail Pharmacies 13.19.2. Online pharmacies 13.19.3. Hospital pharmacies 13.20. Middle East & Africa Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis 13.20.1. By Indication Type 13.20.2. By Distribution Channel 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America Anti-angiogenic Ophthalmic Agents Market Analysis 14.1. Key Findings 14.2. South America Anti-angiogenic Ophthalmic Agents Market Overview 14.3. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Indication Type 14.4. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 14.4.1. Myopic Choroidal Neovascularization 14.4.2. Macular Edema 14.4.3. Diabetic Retinopathy 14.4.4. Macular Degeneration 14.5. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Distribution Channel 14.6. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 14.6.1. Retail Pharmacies 14.6.2. Online pharmacies 14.6.3. Hospital pharmacies 14.7. South America Anti-angiogenic Ophthalmic Agents Market Value Share Analysis, By Country 14.8. South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America Anti-angiogenic Ophthalmic Agents Market Analysis, By Country 14.10. Brazil Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 14.10.1. Myopic Choroidal Neovascularization 14.10.2. Macular Edema 14.10.3. Diabetic Retinopathy 14.10.4. Macular Degeneration 14.11. Brazil Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 14.11.1. Retail Pharmacies 14.11.2. Online pharmacies 14.11.3. Hospital pharmacies 14.12. Colombia Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 14.12.1. Myopic Choroidal Neovascularization 14.12.2. Macular Edema 14.12.3. Diabetic Retinopathy 14.12.4. Macular Degeneration 14.13. Colombia Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 14.13.1. Retail Pharmacies 14.13.2. Online pharmacies 14.13.3. Hospital pharmacies 14.14. Argentina Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 14.14.1. Myopic Choroidal Neovascularization 14.14.2. Macular Edema 14.14.3. Diabetic Retinopathy 14.14.4. Macular Degeneration 14.15. Argentina Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 14.15.1. Retail Pharmacies 14.15.2. Online pharmacies 14.15.3. Hospital pharmacies 14.16. Rest of South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Indication Type 14.16.1. Myopic Choroidal Neovascularization 14.16.2. Macular Edema 14.16.3. Diabetic Retinopathy 14.16.4. Macular Degeneration 14.17. Rest of South America Anti-angiogenic Ophthalmic Agents Market Forecast, By Distribution Channel 14.17.1. Retail Pharmacies 14.17.2. Online pharmacies 14.17.3. Hospital pharmacies 14.18. South America Anti-angiogenic Ophthalmic Agents Market Attractiveness Analysis 14.18.1. By Indication Type 14.18.2. By Distribution Channel 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Component 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Gilead Sciences, Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Eyetech Inc. 15.3.3. Becton, Dickinson and Company 15.3.4. Regeneron Pharmaceuticals, Inc. 15.3.5. Genentech, Inc. 15.3.6. Novartis AG 15.3.7. Allergan plc 15.3.8. Bayer AG 15.3.9. Santen Pharmaceutical Co., Ltd. 15.3.10. Shanghai Pharmaceuticals 15.3.11. Johnson & Johnson 15.3.12. Pfizer 15.3.13. Sun Pharma 15.3.14. Otsuka Pharmaceutical Co. Ltd 15.3.15. Daiichi Sankyo 15.3.16. ERC Labs 15.3.17. Medicom Health care 15.3.18. Implandata ophthalmic products GmbH 15.3.19. The Geuder Group, MORCHER GmbH 15.3.20. Novamedika 16. Primary key Insights

About This Report

Report ID86782
Category Healthcare
Published DateMarch 2021
Updated Date
Contact Us